The National Institute of Allergy and Infectious Diseases awarded a five-year, $15.5 million contract to Inviragen and PharmaJet to continue their work on a needle-free dengue vaccine. The disease, which is transmitted to humans by mosquitoes in tropical and sub-tropical areas, hospitalizes approximately 500,000 people per year.
The joint venture uses Inviragen's DENVax vaccine using PharmaJet's needle-free technology, which uses a jet injection to administer vaccines and other medications.
AUTHOR: GUESTxwvSQu , [url=http://giwnkiepzkxn.com/]giwnkiepzkxn[/url], [link=http://rmdtblgfxgwr.com/]rmdtblgfxgwr[/link], http://bjbwsdazbvej.com/
AUTHOR: GUESTXae253 , [url=http://nvduwqlafqhw.com/]nvduwqlafqhw[/url], [link=http://jlpkxysoneje.com/]jlpkxysoneje[/link], http://fxpeeakdzdii.com/
AUTHOR: GUEST2TY7s9 <a href="http://rlfoicemstut.com/">rlfoicemstut</a>
AUTHOR: GUESTThanx for that energy, ssutain the nice operate Wonderful operate, I'm likely to commence a modest Website Engine training course perform making use of your website I am hoping you appreciate running a blog with all the common BlogEngine.internet.Thethoughts you express are genuinely amazing. Wish you are going to proper some a lot more posts.